Insider Buying: Bonk (NASDAQ:BNKK) Director Buys $16,440.00 in Stock

Bonk, Inc. (NASDAQ:BNKK) Director Mitchell Austin Rudy bought 12,000 shares of the company’s stock in a transaction that occurred on Wednesday, June 10th. The shares were bought at an average price of $1.37 per share, for a total transaction of $16,440.00. Following the acquisition, the director directly owned 63,341 shares of the company’s stock, valued at $86,777.17. This represents a 23.37% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Mitchell Austin Rudy also recently made the following trade(s):

• On Thursday, April 9th, Mitchell Austin Rudy purchased 31,055 shares of Bonk stock. The shares were bought at an average cost of $2.82 per share, with a total value of $87,575.10.

Bonk Stock Up 9.5%

BNKK stock opened at $1.62 on Friday. The business has a 50 day moving average price of $2.17 and a two-hundred day moving average price of $3.12. The company has a market cap of $12.96 million, a price-to-earnings ratio of -0.35 and a beta of 1.85. Bonk, Inc. has a twelve month low of $1.25 and a twelve month high of $46.90.

Bonk (NASDAQ:BNKK) last posted its quarterly earnings results on Wednesday, May 13th. The company reported ($0.23) earnings per share for the quarter. Bonk had a negative return on equity of 148.62% and a negative net margin of 838.37%.The company had revenue of $0.79 million for the quarter.

Institutional Trading of Bonk

Hedge funds have recently made changes to their positions in the business. Jane Street Group LLC bought a new position in shares of Bonk during the 4th quarter worth approximately $96,000. Geode Capital Management LLC bought a new stake in Bonk in the 4th quarter valued at $128,000. Steward Partners Investment Advisory LLC bought a new stake in Bonk in the 4th quarter valued at $37,000. Finally, State Street Corp bought a new stake in Bonk in the 4th quarter valued at $33,000. 12.55% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of equities analysts recently weighed in on the stock. Wall Street Zen upgraded shares of Bonk from a “sell” rating to a “hold” rating in a report on Saturday, June 13th. Weiss Ratings cut shares of Bonk from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Wednesday, April 29th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat, the stock has a consensus rating of “Sell”.

Bonk Company Profile

Safety Shot, Inc, a wellness and functional beverage company, engages in the research and development of over-the-counter products and intellectual property. Its products pipeline includes Photocil to address psoriasis and vitiligo; JW-700 to treat hair loss; JW-500 for women’s sexual wellness; NoStingz, a jellyfish sting prevention sunscreen; and JW-110 for the treatment of atopic dermatitis/eczema. The company primarily sell its products through third-party physical retail stores and partners. The company was formerly known as Jupiter Wellness, Inc and changed its name to Safety Shot, Inc in September 2023.